LLY

911.65

+0.96%↑

JNJ

235.8

+0.14%↑

ABBV

205.01

+0.38%↑

NVS

147.58

+1.16%↑

AZN

184.25

+0.48%↑

LLY

911.65

+0.96%↑

JNJ

235.8

+0.14%↑

ABBV

205.01

+0.38%↑

NVS

147.58

+1.16%↑

AZN

184.25

+0.48%↑

LLY

911.65

+0.96%↑

JNJ

235.8

+0.14%↑

ABBV

205.01

+0.38%↑

NVS

147.58

+1.16%↑

AZN

184.25

+0.48%↑

LLY

911.65

+0.96%↑

JNJ

235.8

+0.14%↑

ABBV

205.01

+0.38%↑

NVS

147.58

+1.16%↑

AZN

184.25

+0.48%↑

LLY

911.65

+0.96%↑

JNJ

235.8

+0.14%↑

ABBV

205.01

+0.38%↑

NVS

147.58

+1.16%↑

AZN

184.25

+0.48%↑

Search

Omnicell Inc

Fechado

SetorSaúde

34.17 3.36

Visão Geral

Variação de preço das ações

24h

Atual

Mín

32.66

Máximo

34.56

Indicadores-chave

By Trading Economics

Rendimento

-7.5M

-2M

Vendas

3.4M

314M

P/E

Médio do Setor

857.25

57.833

EPS

0.51

Margem de lucro

-0.645

Funcionários

3,580

EBITDA

-9.8M

21M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+75.88% upside

Dividendos

By Dow Jones

Próximos Ganhos

5 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-679M

1.6B

Abertura anterior

30.81

Fecho anterior

34.17

Sentimento de Notícias

By Acuity

50%

50%

144 / 350 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bearish Evidence

Omnicell Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

23 de mar. de 2026, 23:47 UTC

Aquisições, Fusões, Aquisições de Empresas

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

23 de mar. de 2026, 22:55 UTC

Aquisições, Fusões, Aquisições de Empresas

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

23 de mar. de 2026, 21:51 UTC

Aquisições, Fusões, Aquisições de Empresas

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

23 de mar. de 2026, 23:59 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

23 de mar. de 2026, 23:59 UTC

Conversa de Mercado

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

23 de mar. de 2026, 23:50 UTC

Conversa de Mercado

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

23 de mar. de 2026, 23:37 UTC

Conversa de Mercado

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

23 de mar. de 2026, 22:42 UTC

Conversa de Mercado
Notícias Principais

Global Equities Roundup: Market Talk

23 de mar. de 2026, 22:42 UTC

Conversa de Mercado
Notícias Principais

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

23 de mar. de 2026, 22:40 UTC

Aquisições, Fusões, Aquisições de Empresas

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

23 de mar. de 2026, 22:23 UTC

Conversa de Mercado

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

23 de mar. de 2026, 22:22 UTC

Aquisições, Fusões, Aquisições de Empresas

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

23 de mar. de 2026, 22:21 UTC

Aquisições, Fusões, Aquisições de Empresas

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

23 de mar. de 2026, 22:21 UTC

Aquisições, Fusões, Aquisições de Empresas

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

23 de mar. de 2026, 22:20 UTC

Aquisições, Fusões, Aquisições de Empresas

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

23 de mar. de 2026, 22:20 UTC

Aquisições, Fusões, Aquisições de Empresas

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

23 de mar. de 2026, 22:19 UTC

Aquisições, Fusões, Aquisições de Empresas

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

23 de mar. de 2026, 22:19 UTC

Aquisições, Fusões, Aquisições de Empresas

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

23 de mar. de 2026, 22:18 UTC

Aquisições, Fusões, Aquisições de Empresas

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

23 de mar. de 2026, 22:15 UTC

Aquisições, Fusões, Aquisições de Empresas

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

23 de mar. de 2026, 22:08 UTC

Conversa de Mercado

Ebos Needs to Reset Its Gearing Targets -- Market Talk

23 de mar. de 2026, 21:42 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

23 de mar. de 2026, 21:42 UTC

Conversa de Mercado

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

23 de mar. de 2026, 21:32 UTC

Ganhos

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

23 de mar. de 2026, 21:32 UTC

Ganhos

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

23 de mar. de 2026, 21:32 UTC

Ganhos

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

23 de mar. de 2026, 21:10 UTC

Notícias Principais

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

23 de mar. de 2026, 20:50 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

23 de mar. de 2026, 20:50 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

23 de mar. de 2026, 20:50 UTC

Conversa de Mercado
Ganhos
Notícias Principais

Basic Materials Roundup: Market Talk

Comparação entre Pares

Variação de preço

Omnicell Inc Previsão

Preço-alvo

By TipRanks

75.88% parte superior

Previsão para 12 meses

Média 58.2 USD  75.88%

Máximo 70 USD

Mínimo 49 USD

Com base em 7 analistas de Wall Street que oferecem metas de preço de 12 meses para Omnicell Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

7 ratings

6

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

24.23 / 30.44Suporte e Resistência

Curto Prazo

Strong Bearish Evidence

Médio Prazo

Strong Bearish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

144 / 350 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Omnicell Inc

Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots; and inventory management software. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.
help-icon Live chat